AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of ADP-ribose glycohydrolase OARD1 including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into ADP-ribose glycohydrolase OARD1 therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of ADP-ribose glycohydrolase OARD1, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on ADP-ribose glycohydrolase OARD1. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of ADP-ribose glycohydrolase OARD1. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for ADP-ribose glycohydrolase OARD1 includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
ADP-ribose glycohydrolase OARD1
partner:
Reaxense
upacc:
Q9Y530
UPID:
OARD1_HUMAN
Alternative names:
O-acetyl-ADP-ribose deacetylase 1; Terminal ADP-ribose protein glycohydrolase 1; [Protein ADP-ribosylglutamate] hydrolase OARD1
Alternative UPACC:
Q9Y530; A6NEK4; A8K4H4; Q96F23
Background:
ADP-ribose glycohydrolase OARD1, known alternatively as O-acetyl-ADP-ribose deacetylase 1, Terminal ADP-ribose protein glycohydrolase 1, and [Protein ADP-ribosylglutamate] hydrolase OARD1, plays a crucial role in cellular processes. It hydrolyzes ADP-ribose, acting on substrates like proteins ADP-ribosylated on glutamate and O-acetyl-ADP-D-ribose. OARD1 specifically acts as a glutamate mono-ADP-ribosylhydrolase, removing mono-ADP-ribose attached to glutamate residues on proteins. It does not act on poly-ADP-ribosylated proteins but can deacetylate O-acetyl-ADP ribose, a signaling molecule generated by the deacetylation of acetylated lysine residues in histones and other proteins.
Therapeutic significance:
Understanding the role of ADP-ribose glycohydrolase OARD1 could open doors to potential therapeutic strategies.
